Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 703 participants.

Also called NCT02906930

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 703 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02906930
  • EudraCT 2015-005622-19
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials Diabetes, obesity & metabolism, 2021-12 DOI, PubMed 34472698, PMC9293331 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Bulgaria, Czechia, Italy, Japan, Mexico, Romania, Russia, Serbia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02906930. Randomized; double masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2017-10-30 (actual). Results posted on 2020-02-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
Acronym
PIONEER 1
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02906930
Content hash
feab280d5bad5f4232347cbba91d3b7dcdadb51cb4449a40f4775e83f0d222fc